Georgian medical news · 2024
THE EFFECT OF INTRANASAL ADMINISTRATION OF BIOLOGICALLY ACTIVE SUBSTANCES OF AMINO ACID AND PEPTIDE NATURE ON THE MONOAMINE SYSTEMS OF THE BRAIN.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Apryatin S, Moiseenko V, Gainetdinov R, Apryatina V
Аннотация
INTRODUCTION: The annual growth of psychiatric and neurodegenerative diseases requires new therapeutic strategies for delivering active pharmaceutical molecules to the brain. Non-invasive intranasal drug delivery is a promising method that allows bypassing of the blood-brain barrier and the liver de-toxification system.
RESULTS: The review discusses the main results of experimental studies of the effect of intranasal substances of amino acid and peptide nature on the monoamine systems of the brain. The main attention is paid to understanding the transport mechanisms of potential amino acid and peptide drugs in the nose-to-brain projection and assessing their therapeutic efficacy.
CONCLUSION: The obtained results indicate the possibility of creating, along with buccal, in-halation, transdermal and ocular preparations, intranasal non-invasive drugs that provide more effective therapy for psychiatric and neurodegenerative diseases, such as schizophrenia, depression, anxiety, ADHD, Alzheimer disease and Parkinson disease.
RESULTS: The review discusses the main results of experimental studies of the effect of intranasal substances of amino acid and peptide nature on the monoamine systems of the brain. The main attention is paid to understanding the transport mechanisms of potential amino acid and peptide drugs in the nose-to-brain projection and assessing their therapeutic efficacy.
CONCLUSION: The obtained results indicate the possibility of creating, along with buccal, in-halation, transdermal and ocular preparations, intranasal non-invasive drugs that provide more effective therapy for psychiatric and neurodegenerative diseases, such as schizophrenia, depression, anxiety, ADHD, Alzheimer disease and Parkinson disease.